Avidity biosciences announces pricing of upsized public offering of common stock

San diego , aug. 14, 2024 /prnewswire/ -- avidity biosciences, inc. (nasdaq: rna), a biopharmaceutical company committed to delivering a new class of rna therapeutics called antibody oligonucleotide conjugates (aocs™), today announced the pricing of its upsized underwritten public offering of 7,320,000 shares of its common stock at a price to the public of $41.00 per share. all of the shares to be sold in the offering are to be sold by avidity.
RNA Ratings Summary
RNA Quant Ranking